DataMeds AI licenses exclusive U.S. rights to Reboot Health AI's GLP-1 management platform
MEDS•DataMeds AI licensed exclusive U.S. direct-to-consumer rights to Reboot Health AI's GLP-1 care management platform. It will be integrated into the Health Lives Here app through monthly subscriptions, with revenue shared between the companies; the license covers six patents and six pending applications.
1. Platform license
DataMeds AI entered an exclusive agreement to license U.S. direct-to-consumer rights to Reboot Health AI's care management platform for GLP-1 patients. The platform will be integrated into the Health Lives Here app through monthly subscriptions, with revenue shared between the companies. The license covers intellectual property comprising six patents and six pending patent applications.
